{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:35:08Z","timestamp":1786980908716,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"AlJalila foundation for medical education","award":["AJF201612"],"award-info":[{"award-number":["AJF201612"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,4,15]]},"DOI":"10.1007\/s10637-018-0626-5","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T21:39:13Z","timestamp":1530049153000},"page":"252-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Inhibition of SHP2 by new compounds induces differential effects on RAS\/RAF\/ERK and PI3K\/AKT pathways in different cancer cell types"],"prefix":"10.1007","volume":"37","author":[{"given":"Cijo George","family":"Vazhappilly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekram","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafaa","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya Mudhafar","family":"Al-Azawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamadeh","family":"Tarazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajjaj","family":"Abdu-Allah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel-Nasser","family":"El-Shorbagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raafat","family":"El-Awady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,27]]},"reference":[{"key":"626_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12094-006-0005-0","volume":"8","author":"J-J Ventura","year":"2006","unstructured":"Ventura J-J, Nebreda AR (2006) Protein kinases and phosphatases as therapeutic targets in cancer. Clin Transl Oncol 8:153\u2013160. https:\/\/doi.org\/10.1007\/s12094-006-0005-0","journal-title":"Clin Transl Oncol"},{"key":"626_CR2","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1111\/jcmm.12618","volume":"19","author":"J Zhang","year":"2015","unstructured":"Zhang J, Zhang F, Niu R (2015) Functions of Shp2 in cancer. J Cell Mol Med 19:2075\u20132083. https:\/\/doi.org\/10.1111\/jcmm.12618","journal-title":"J Cell Mol Med"},{"key":"626_CR3","doi-asserted-by":"publisher","unstructured":"Zhao S, Sedwick D, Wang Z (2014) Genetic alterations of protein tyrosine phosphatases in human cancers. Oncogene:1\u201310. https:\/\/doi.org\/10.1038\/onc.2014.326","DOI":"10.1038\/onc.2014.326"},{"key":"626_CR4","doi-asserted-by":"publisher","unstructured":"Han T, Xiang D-M, Sun W, Liu N, Sun H-L, Wen W, Shen W-F, Wang R-Y, Chen C, Wang X, Cheng Z, Li H-Y, Wu M-C, Cong W-M, Feng G-S, Ding J, Wang H-Y (2015) PTPN11\/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients. J Hepatol 63. https:\/\/doi.org\/10.1016\/j.jhep.2015.03.036","DOI":"10.1016\/j.jhep.2015.03.036"},{"key":"626_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0065-230X(10)06002-1","volume":"106","author":"KS Grossmann","year":"2010","unstructured":"Grossmann KS, Ros\u00e1rio M, Birchmeier C, Birchmeier W (2010) The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res 106:53\u201389. https:\/\/doi.org\/10.1016\/S0065-230X(10)06002-1","journal-title":"Adv Cancer Res"},{"key":"626_CR6","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/cdd.2008.54","volume":"15","author":"XD Zhou","year":"2008","unstructured":"Zhou XD, Agazie YM (2008) Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells. Cell Death Differ 15:988\u2013996. https:\/\/doi.org\/10.1038\/cdd.2008.54","journal-title":"Cell Death Differ"},{"key":"626_CR7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cellsig.2007.10.002","volume":"20","author":"M Dance","year":"2008","unstructured":"Dance M, Montagner A, Salles JP, Yart A, Raynal P (2008) The molecular functions of Shp2 in the Ras\/Mitogen-activated protein kinase (ERK1\/2) pathway. Cell Signal 20:453\u2013459. https:\/\/doi.org\/10.1016\/j.cellsig.2007.10.002","journal-title":"Cell Signal"},{"key":"626_CR8","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.4155\/fmc.14.88","volume":"6","author":"S Butterworth","year":"2014","unstructured":"Butterworth S, Overduin M, Barr AJ (2014) Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention. Future Med Chem 6:1423\u20131437. https:\/\/doi.org\/10.4155\/fmc.14.88","journal-title":"Future Med Chem"},{"key":"626_CR9","doi-asserted-by":"publisher","first-page":"53518","DOI":"10.18632\/oncotarget.18591","volume":"8","author":"Z Liu","year":"2017","unstructured":"Liu Z, Zhao Y, Fang J, Cui R, Xiao Y, Xu Q, Liu Z, Zhao Y, Fang J, Cui R, Xiao Y, Xu Q (2017) SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells. Oncotarget 8:53518\u201353530. https:\/\/doi.org\/10.18632\/oncotarget.18591","journal-title":"Oncotarget"},{"key":"626_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nm.2645","volume":"18","author":"N Aceto","year":"2012","unstructured":"Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G, Confalonieri S, Quarto M, Hu G, Balwierz PJ, Pachkov M, Elledge SJ, van Nimwegen E, Stadler MB, Bentires-Alj M (2012) Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med 18:529\u2013537. https:\/\/doi.org\/10.1038\/nm.2645","journal-title":"Nat Med"},{"key":"626_CR11","doi-asserted-by":"publisher","unstructured":"Wu D, Pang Y, Ke Y, Yu J, He Z, Tautz L, Mustelin T, Ding S, Huang Z, Feng GS (2009) A conserved mechanism for control of human and mouse embryonic stem cell pluripotency and differentiation by Shp2 tyrosine phosphatase. PLoS One 4. https:\/\/doi.org\/10.1371\/journal.pone.0004914","DOI":"10.1371\/journal.pone.0004914"},{"key":"626_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nature18621","volume":"535","author":"Y-NP Chen","year":"2016","unstructured":"Chen Y-NP, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH-T, Chen Z, Cooke VG, Dobson JR, Deng Z, Fei F, Firestone B, Fodor M, Fridrich C, Gao H, Grunenfelder D, Hao H-X, Jacob J, Ho S, Hsiao K, Kang ZB, Karki R, Kato M, Larrow J, La Bonte LR, Lenoir F, Liu G, Liu S, Majumdar D, Meyer MJ, Palermo M, Perez L, Pu M, Price E, Quinn C, Shakya S, Shultz MD, Slisz J, Venkatesan K, Wang P, Warmuth M, Williams S, Yang G, Yuan J, Zhang J-H, Zhu P, Ramsey T, Keen NJ, Sellers WR, Stams T, Fortin PD (2016) Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 535:148\u2013152. https:\/\/doi.org\/10.1038\/nature18621","journal-title":"Nature"},{"key":"626_CR13","doi-asserted-by":"publisher","unstructured":"Abdu Allah HH, El Shorbagi ANA (2016) 5-Aminosalyclic Acid (5-ASA): A Unique Anti-Inflammatory Salicylate. Med Chem (Los Angeles) 6. https:\/\/doi.org\/10.4172\/2161-0444.1000361","DOI":"10.4172\/2161-0444.1000361"},{"key":"626_CR14","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.bmcl.2016.02.073","volume":"26","author":"HHM Abdu-Allah","year":"2016","unstructured":"Abdu-Allah HHM, Abdel-Moty SG, El-Awady R, El-Shorbagi ANA (2016) Design and synthesis of novel 5-aminosalicylate (5-ASA)\u20134-thiazolinone hybrid derivatives with promising antiproliferative activity. Bioorg Med Chem Lett 26:1647\u20131650. https:\/\/doi.org\/10.1016\/j.bmcl.2016.02.073","journal-title":"Bioorg Med Chem Lett"},{"key":"626_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334.AutoDock","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson A (2010) AutoDock Vina: inproving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 31:455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334.AutoDock","journal-title":"J Comput Chem"},{"key":"626_CR16","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.4161\/cbt.21078","volume":"13","author":"EM Saleh","year":"2012","unstructured":"Saleh EM, El-awady RA, Eissa NA, Abdel-Rahman WM (2012) Antagonism between curcumin and the topoisomerase II inhibitor etoposide: A study of DNA damage, cell cycle regulation and death pathways. Cancer Biol Ther 13:1058\u20131071. https:\/\/doi.org\/10.4161\/cbt.21078","journal-title":"Cancer Biol Ther"},{"key":"626_CR17","doi-asserted-by":"publisher","first-page":"e51046","DOI":"10.3791\/51046","volume":"752","author":"CR Justus","year":"2014","unstructured":"Justus CR, Leffler N, Ruiz-Echevarria M, Yang LV (2014) In vitro cell migration and invasion assays. J Vis Exp 752:e51046. https:\/\/doi.org\/10.3791\/51046","journal-title":"J Vis Exp"},{"key":"626_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/CAD.0b013e328334b0ae","volume":"21","author":"RA El-Awady","year":"2010","unstructured":"El-Awady RA, Saleh EM, Dahm-Daphi J (2010) Targeting DNA double-strand break repair: Is it the right way for sensitizing cells to 5-fluorouracil? Anti-Cancer Drugs 21:277\u2013287. https:\/\/doi.org\/10.1097\/CAD.0b013e328334b0ae","journal-title":"Anti-Cancer Drugs"},{"key":"626_CR19","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/aps.2014.80","volume":"35","author":"R He","year":"2014","unstructured":"He R, Yu Z, Zhang R, Zhang Z (2014) Protein tyrosine phosphatases as potential therapeutic targets. Acta Pharmacol Sin 35:1227\u20131246. https:\/\/doi.org\/10.1038\/aps.2014.80","journal-title":"Acta Pharmacol Sin"},{"key":"626_CR20","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.celrep.2015.08.037","volume":"12","author":"A Prahallad","year":"2015","unstructured":"Prahallad A, Heynen GJJE, Germano G, Willems SM, Evers B, Vecchione L, Gambino V, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Bernards R (2015) PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. Cell Rep 12:1978\u20131985. https:\/\/doi.org\/10.1016\/j.celrep.2015.08.037","journal-title":"Cell Rep"},{"key":"626_CR21","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.18632\/oncotarget.3356","volume":"6","author":"VE Schneeberger","year":"2015","unstructured":"Schneeberger VE, Ren Y, Luetteke N, Huang Q, Chen L, Lawrence HR, Lawrence NJ, Haura EB, Koomen JM, Coppola D, Wu J (2015) Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma. Oncotarget 6:6191\u20136202. https:\/\/doi.org\/10.18632\/oncotarget.3356","journal-title":"Oncotarget"},{"key":"626_CR22","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/0008-5472.CAN-04-0396","volume":"64","author":"LB Eckert","year":"2004","unstructured":"Eckert LB, Repasky GA, Ulk\u00fc AS, McFall A, Zhou H, Sartor CI, Der CJ (2004) Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res 64:4585\u20134592. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0396","journal-title":"Cancer Res"},{"key":"626_CR23","doi-asserted-by":"publisher","unstructured":"Perera D, Venkitaraman AR (2016) Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents. Sci Rep 6. https:\/\/doi.org\/10.1038\/srep29741","DOI":"10.1038\/srep29741"},{"key":"626_CR24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","volume":"36","author":"MC Mendoza","year":"2011","unstructured":"Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem Sci 36:320\u2013328. https:\/\/doi.org\/10.1016\/j.tibs.2011.03.006","journal-title":"Trends Biochem Sci"},{"key":"626_CR25","doi-asserted-by":"publisher","first-page":"R589","DOI":"10.1186\/bcr1259","volume":"7","author":"X Li","year":"2005","unstructured":"Li X, Lu Y, Liang K, Liu B, Fan Z (2005) Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Res 7:R589\u2013R597. https:\/\/doi.org\/10.1186\/bcr1259","journal-title":"Breast Cancer Res"},{"key":"626_CR26","doi-asserted-by":"publisher","unstructured":"Li X, Ma H, Li L, Chen Y, Sun X, Dong Z, Liu JY, Zhu W, Zhang JT (2018) Novel synthetic bisindolylmaleimide alkaloids inhibit STAT3 activation by binding to the SH2 domain and suppress breast xenograft tumor growth. Oncogene. https:\/\/doi.org\/10.1038\/s41388-017-0076-0","DOI":"10.1038\/s41388-017-0076-0"},{"key":"626_CR27","doi-asserted-by":"publisher","unstructured":"Magi S, Tashiro E, Imoto M (2012) A chemical genomic study identifying diversity in cell migration signaling in cancer cells. Sci Rep 2. https:\/\/doi.org\/10.1038\/srep00823","DOI":"10.1038\/srep00823"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0626-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0626-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0626-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T13:29:51Z","timestamp":1678541391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0626-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,27]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4,15]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0626-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,27]]},"assertion":[{"value":"11 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Author CV declares that he has no conflict of interest. Author ES declares that he has no conflict of interest. Author WR declares that he has no conflict of interest. Author VM declares that he has no conflict of interest. Author AA declares that he has no conflict of interest. Author HT declares that he has no conflict of interest. Author HA declares that he has no conflict of interest. Author AE declares that he has no conflict of interest. Author RE declares that he has no conflict of interest","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}